CLINICAL TRIALS PROFILE FOR TOLAZAMIDE
✉ Email this page to a colleague
All Clinical Trials for TOLAZAMIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02456428 ↗ | Incretin-based Drugs and the Risk of Heart Failure | Completed | Canadian Institutes of Health Research (CIHR) | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs. | |
| NCT02456428 ↗ | Incretin-based Drugs and the Risk of Heart Failure | Completed | Drug Safety and Effectiveness Network, Canada | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs. | |
| NCT02456428 ↗ | Incretin-based Drugs and the Risk of Heart Failure | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs. | |
| NCT02475499 ↗ | Incretin-based Drugs and Pancreatic Cancer | Completed | Canadian Institutes of Health Research (CIHR) | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer (PC) compared to sulfonylureas. The investigators will carry out separate population based cohort studies using administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for PC. The results from the separate sites will be combined to provide an overall assessment of the risk of PC in users of incretin-based drugs and by class of incretin-based drugs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOLAZAMIDE
Condition Name
Clinical Trial Locations for TOLAZAMIDE
Clinical Trial Progress for TOLAZAMIDE
Clinical Trial Phase
Clinical Trial Sponsors for TOLAZAMIDE
Sponsor Name
| Sponsor Name for TOLAZAMIDE | |
| Sponsor | Trials |
| Canadian Institutes of Health Research (CIHR) | 3 |
| Drug Safety and Effectiveness Network, Canada | 3 |
| Canadian Network for Observational Drug Effect Studies, CNODES | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
